Patents by Inventor Robert Flaumenhaft

Robert Flaumenhaft has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR TREATING SICKLE CELL DISEASE USING QUERCETIN-CONTAINING COMPOSITIONS
    Publication number: 20250375411
    Abstract: Disclosed are compositions and methods for treating sickle cell disease. Also disclosed are methods of treating sickle cell disease comprising administering to a subject in need thereof an effective amount of isoquercetin, vitamin B3, vitamin C, and optionally folic acid and wherein the effective amount is sufficient to halt progression of one or more of the symptoms of sickle cell disease.
    Type: Application
    Filed: August 25, 2025
    Publication date: December 11, 2025
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Jeffrey I. ZWICKER, Bruce FURIE, Robert FLAUMENHAFT
  • Method for treating sickle cell disease using quercetin-containing compositions
    Patent number: 12403123
    Abstract: Disclosed are compositions and methods for treating sickle cell disease. Also disclosed are methods of treating sickle cell disease comprising administering to a subject in need thereof an effective amount of isoquercetin, vitamin B3, vitamin C, and optionally folic acid and wherein the effective amount is sufficient to halt progression of one or more of the symptoms of sickle cell disease.
    Type: Grant
    Filed: July 15, 2022
    Date of Patent: September 2, 2025
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Jeffrey I. Zwicker, Bruce Furie, Robert Flaumenhaft
  • COMPOSITIONS AND METHODS FOR REDUCING MAJOR THROMBOTIC EVENTS IN CANCER PATIENTS
    Publication number: 20250262232
    Abstract: The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.
    Type: Application
    Filed: April 25, 2025
    Publication date: August 21, 2025
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Jeffrey I. ZWICKER, Bruce FURIE, Jack Davis STOPA, Robert FLAUMENHAFT
  • COMPOSITIONS AND METHODS FOR EVALUATION OF ANTIPLATELET DRUG SENSITIVITY
    Publication number: 20250189545
    Abstract: In some aspects, the disclosure relates to compositions and methods for detecting phosphorylation of dynamin-related protein 1 (Drp1) at position Ser-616. In some embodiments, methods described by the disclosure are useful for detecting antiplatelet agent sensitivity in a subject. In some embodiments, methods described by the disclosure are useful for detecting if a subject has been previously exposed to an antiplatelet agent.
    Type: Application
    Filed: January 17, 2025
    Publication date: June 12, 2025
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Robert Flaumenhaft, David Barrios, Secil Koseoglu
  • ANTI-PROTHROMBIN ANTIBODIES TARGETING THE OPEN FORM OF PROTHROMBIN
    Publication number: 20250163181
    Abstract: Antigen-binding proteins including monoclonal antibodies (mAbs) against prothrombin, which bind to the open form of prothrombin and decrease conversion of prothrombin to thrombin are provided. Antibody fragments and conjugates are also provided. Anticoagulant pharmaceutical compositions based on the monoclonal antibodies against prothrombin and fragments and conjugates thereof are also provided, along with methods for treating and preventing blood clots and for reducing thrombin generation in patients.
    Type: Application
    Filed: November 15, 2024
    Publication date: May 22, 2025
    Inventors: Nicola Pozzi, Robert Flaumenhaft
  • Compositions and methods for reducing major thrombotic events in cancer patients
    Patent number: 12290527
    Abstract: The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.
    Type: Grant
    Filed: January 12, 2024
    Date of Patent: May 6, 2025
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Jeffrey I. Zwicker, Bruce Furie, Jack Davis Stopa, Robert Flaumenhaft
  • COMPOUNDS AND METHODS FOR USING GALLOYLATED POLYPHENOLS TO TREAT DISEASES MEDIATED BY THIOL ISOMERASES
    Publication number: 20250134853
    Abstract: Provided herein are galloylated polyphenols useful in inhibiting thrombosis formation. Also provided herein are methods of treating or preventing thrombosis in a subject in need thereof that include administering to the subject a galloylated polyphenol, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 31, 2024
    Publication date: May 1, 2025
    Inventors: Robert Flaumenhaft, Moua Yang
  • Compositions and methods for evaluation of antiplatelet drug sensitivity
    Patent number: 12235278
    Abstract: In some aspects, the disclosure relates to compositions and methods for detecting phosphorylation of dynamin-related protein 1 (Dip1) at position Ser-616. In some embodiments, methods described by the disclosure are useful for detecting antiplatelet agent sensitivity in a subject. In some embodiments, methods described by the disclosure are useful for detecting if a subject has been previously exposed to an antiplatelet agent.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: February 25, 2025
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Robert Flaumenhaft, David Barrios, Secil Koseoglu
  • COMPOSITIONS AND METHODS FOR REDUCING MAJOR THROMBOTIC EVENTS IN CANCER PATIENTS
    Publication number: 20240285659
    Abstract: The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.
    Type: Application
    Filed: January 12, 2024
    Publication date: August 29, 2024
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Jeffrey I. ZWICKER, Bruce FURIE, Jack Davis STOPA, Robert FLAUMENHAFT
  • COMPOSITIONS AND METHODS FOR IDENTIFYING AND MODULATING THROMBOTIC CONDITIONS IN A CANCER PATIENT
    Publication number: 20240133897
    Abstract: The present invention relates to compositions and methods for identifying at-risk patients and modulating thrombotic conditions in a cancer patient. Embodiments provided herein include a method of determining risk for a thrombotic event in a cancer patient comprising: detecting in a sample of a patient with cancer elevated levels of PPIA, PDIA3 and at least one of EIF5A, EIF4H, EIF4a3, UBE2N, UBE2L3, UBE2I, and HSP70.
    Type: Application
    Filed: December 9, 2020
    Publication date: April 25, 2024
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Jeffrey I. Zwicker, Robert Flaumenhaft
  • COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS
    Publication number: 20240016777
    Abstract: The present application provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions containing the compound of Formula (I), and methods of using the compound of Formula (I) for treating viral infections and inhibiting thromobosis are also provided.
    Type: Application
    Filed: November 12, 2021
    Publication date: January 18, 2024
    Inventors: Robert Flaumenhaft, Lin Lin
  • Compositions and methods for reducing major thrombotic events in cancer patients
    Patent number: 11872241
    Abstract: The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: January 16, 2024
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Jeffrey I. Zwicker, Bruce Furie, Jack Davis Stopa, Robert Flaumenhaft
  • METHOD FOR TREATING SICKLE CELL DISEASE USING QUERCETIN-CONTAINING COMPOSITIONS
    Publication number: 20230029216
    Abstract: Disclosed are compositions and methods for treating sickle cell disease. Also disclosed are methods of treating sickle cell disease comprising administering to a subject in need thereof an effective amount of isoquercetin, vitamin B3, vitamin C, and optionally folic acid and wherein the effective amount is sufficient to halt progression of one or more of the symptoms of sickle cell disease.
    Type: Application
    Filed: July 15, 2022
    Publication date: January 26, 2023
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Jeffrey I. ZWICKER, Bruce FURIE, Robert FLAUMENHAFT
  • COMPOSITIONS AND METHODS FOR EVALUATION OF ANTIPLATELET DRUG SENSITIVITY
    Publication number: 20210181214
    Abstract: In some aspects, the disclosure relates to compositions and methods for detecting phosphorylation of dynamin-related protein 1 (Dip1) at position Ser-616. In some embodiments, methods described by the disclosure are useful for detecting antiplatelet agent sensitivity in a subject. In some embodiments, methods described by the disclosure are useful for detecting if a subject has been previously exposed to an antiplatelet agent.
    Type: Application
    Filed: August 23, 2019
    Publication date: June 17, 2021
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Robert Flaumenhaft, David Barrios, Secil Koseoglu
  • COMPOSITIONS AND METHODS FOR REDUCING MAJOR THROMBOTIC EVENTS IN CANCER PATIENTS
    Publication number: 20200171064
    Abstract: The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.
    Type: Application
    Filed: November 26, 2019
    Publication date: June 4, 2020
    Inventors: Jeffrey I. ZWICKER, Bruce FURIE, Jack Davis STOPA, Robert FLAUMENHAFT
  • COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEIN DISULFIDE ISOMERASE
    Publication number: 20180370912
    Abstract: Provided herein are compounds of Formula I: and pharmaceutically acceptable salts and compositions thereof for use in treating diseases associated with the activity or expression of protein disulfide isomerase, wherein the variables are as described herein.
    Type: Application
    Filed: June 29, 2017
    Publication date: December 27, 2018
    Inventors: Robert Flaumenhaft, Partha Pratim Nag
  • Compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase
    Patent number: 10064853
    Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: September 4, 2018
    Assignees: Beth Israel Deaconess Medical Center, Inc., The Broad Institute, Inc.
    Inventors: Robert Flaumenhaft, Partha Pratim Nag, Tatiana Pilyugina, Jun Pu, Sivaraman Dandapani, Benito Munoz, Chris Dockendorff
  • COMPOUNDS AND COMPOUNDS FOR USE IN METHODS FOR TREATING DISEASES OR CONDITIONS MEDIATED BY PROTEIN DISULFIDE ISOMERASE
    Publication number: 20170304283
    Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI. Formula (I).
    Type: Application
    Filed: June 26, 2017
    Publication date: October 26, 2017
    Inventors: Robert Flaumenhaft, Partha Pratim Nag, Tatiana Pilyugina, Jun Pu, Sivaraman Dandapani, Benito Munoz, Chris Dockendorff
  • Compounds and methods for treating diseases mediated by protease activated receptors
    Patent number: 9422262
    Abstract: The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: August 23, 2016
    Assignees: The Broad Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Chris Dockendorff, Robert Flaumenhaft
  • COMPOUNDS AND COMPOUNDS FOR USE IN METHODS FOR TREATING DISEASES OR CONDITIONS MEDIATED BY PROTEIN DISULFIDE ISOMERASE
    Publication number: 20160145209
    Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI.
    Type: Application
    Filed: June 20, 2014
    Publication date: May 26, 2016
    Inventors: Robert Flaumenhaft, Partha Pratim Nag, Tatiana Pilyugina, Jun Pu, Sivaraman Dandapani, Benito Munoz